Cargando…

Enriching limited information on rare diseases from heterogeneous networks for drug repositioning

BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Hongkui, Zhang, Liang, Jin, Bo, Cheng, Shicheng, Wei, Xiaopeng, Che, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596891/
https://www.ncbi.nlm.nih.gov/pubmed/34789254
http://dx.doi.org/10.1186/s12911-021-01664-x
_version_ 1784600491280302080
author Cao, Hongkui
Zhang, Liang
Jin, Bo
Cheng, Shicheng
Wei, Xiaopeng
Che, Chao
author_facet Cao, Hongkui
Zhang, Liang
Jin, Bo
Cheng, Shicheng
Wei, Xiaopeng
Che, Chao
author_sort Cao, Hongkui
collection PubMed
description BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict drugs for the rare disease. METHOD: In this paper, we focus on father–son information mining for the rare disease. We propose GRU-Cooperation-Attention-Network (GCAN) to predict drugs for the rare disease. We construct two heterogeneous networks for information enhancement, one network contains the father-nodes of the rare disease and the other network contains the son-nodes information. To bridge two heterogeneous networks, we set a mapping to connect them. What’s more, we use the biased random walk mechanism to collect the information smoothly from two heterogeneous networks, and employ a cooperation attention mechanism to enhance repositioning ability of the network. RESULT: Comparing with traditional methods, GCAN makes full use of father–son information. The experimental results on real drug data from hospitals show that GCAN outperforms state-of-the-art machine learning methods for drug repositioning. CONCLUSION: The performance of GCAN for drug repositioning is mainly limited by the insufficient scale and poor quality of the data. In future research work, we will focus on how to utilize more data such as drug molecule information and protein molecule information for the drug repositioning of the rare disease.
format Online
Article
Text
id pubmed-8596891
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85968912021-11-17 Enriching limited information on rare diseases from heterogeneous networks for drug repositioning Cao, Hongkui Zhang, Liang Jin, Bo Cheng, Shicheng Wei, Xiaopeng Che, Chao BMC Med Inform Decis Mak Research BACKGROUND: The historical data of rare disease is very scarce in reality, so how to perform drug repositioning for the rare disease is a great challenge. Most existing methods of drug repositioning for the rare disease usually neglect father–son information, so it is extremely difficult to predict drugs for the rare disease. METHOD: In this paper, we focus on father–son information mining for the rare disease. We propose GRU-Cooperation-Attention-Network (GCAN) to predict drugs for the rare disease. We construct two heterogeneous networks for information enhancement, one network contains the father-nodes of the rare disease and the other network contains the son-nodes information. To bridge two heterogeneous networks, we set a mapping to connect them. What’s more, we use the biased random walk mechanism to collect the information smoothly from two heterogeneous networks, and employ a cooperation attention mechanism to enhance repositioning ability of the network. RESULT: Comparing with traditional methods, GCAN makes full use of father–son information. The experimental results on real drug data from hospitals show that GCAN outperforms state-of-the-art machine learning methods for drug repositioning. CONCLUSION: The performance of GCAN for drug repositioning is mainly limited by the insufficient scale and poor quality of the data. In future research work, we will focus on how to utilize more data such as drug molecule information and protein molecule information for the drug repositioning of the rare disease. BioMed Central 2021-11-16 /pmc/articles/PMC8596891/ /pubmed/34789254 http://dx.doi.org/10.1186/s12911-021-01664-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cao, Hongkui
Zhang, Liang
Jin, Bo
Cheng, Shicheng
Wei, Xiaopeng
Che, Chao
Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title_full Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title_fullStr Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title_full_unstemmed Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title_short Enriching limited information on rare diseases from heterogeneous networks for drug repositioning
title_sort enriching limited information on rare diseases from heterogeneous networks for drug repositioning
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596891/
https://www.ncbi.nlm.nih.gov/pubmed/34789254
http://dx.doi.org/10.1186/s12911-021-01664-x
work_keys_str_mv AT caohongkui enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning
AT zhangliang enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning
AT jinbo enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning
AT chengshicheng enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning
AT weixiaopeng enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning
AT chechao enrichinglimitedinformationonrarediseasesfromheterogeneousnetworksfordrugrepositioning